Leqembi Iqlik US launch

On August 24, 2026, Eisai announced that Leqembi Iqlik (lecanemab-irmb subcutaneous injection), approved by the FDA on July 13, is now available in the US for initiation therapy for early Alzheimer's disease. This is the first anti-amyloid treatment offering at-home dosing via an autoinjector for both initiation and maintenance, providing a convenient alternative to IV infusion. The launch expands patient convenience and may reduce healthcare resource utilization. Leqembi is approved in 53 countries and under review in 6. BioArctic, which invented lecanemab, is entitled to royalties and sales milestones from Eisai. The event also highlights ongoing regulatory progress in Japan and China, and ongoing clinical studies such as AHEAD 3-45 and Tau NexGen.